Evidence map›Paper›PMID 37966090›Full record

ArticleAntimicrobial agents and chemotherapy2023

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.

Deepak Almeida, Si-Yang Li, Jin Lee, Barry Hafkin, Khisimuzi Mdluli, Nader Fotouhi, Eric L Nuermberger

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Contezolid in tuberculous meningitis: comparable efficacy and favorable safety.Frontiers in cellular and infection microbiology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Deepak AlmeidaDepartment of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, USA.ORCID 0009-0004-8907-1792
Si-Yang LiDepartment of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, USA.
Jin LeeDepartment of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, USA.
Barry HafkinMicuRx Pharmaceuticals, Foster City, California, USA.
Khisimuzi MdluliGlobal Alliance for Tuberculosis Drug Development, New York, USA.
Nader FotouhiGlobal Alliance for Tuberculosis Drug Development, New York, USA.
Eric L NuermbergerDepartment of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, Maryland, USA.ORCID 0000-0003-1440-9889
Johns Hopkins University · USTB Alliance · US

Funding

Global Alliance for Tuberculosis Drug Development
6 · The paper itself

Abstract

Contezolid is a new oxazolidinone with

Indexed as

Mycobacterium tuberculosisOxazolidinonesTuberculosisTuberculosis, Multidrug-ResistantAnimalsAntitubercular AgentsDiarylquinolinesDisease Models, AnimalLinezolidMiceNitroimidazolesPyridonesAntitubercular AgentsbedaquilinecontezolidDiarylquinolinesLinezolidNitroimidazolesOxazolidinonespretomanidPyridonescontezolidMycobacterium tuberculosisoxazolidinones

Identifiers

PMID37966090
PMCPMC10720489
OpenAlexW4388698871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.